Zacks: Brokerages Anticipate Prestige Consumer Healthcare Inc. (NYSE:PBH) Will Announce Earnings of $0.99 Per Share

Brokerages expect Prestige Consumer Healthcare Inc. (NYSE:PBH) to post earnings per share of $0.99 for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Prestige Consumer Healthcare’s earnings, with estimates ranging from $0.97 to $0.99. Prestige Consumer Healthcare reported earnings of $0.78 per share during the same quarter last year, which indicates a positive year over year growth rate of 26.9%. The company is scheduled to issue its next earnings results on Thursday, November 4th.

On average, analysts expect that Prestige Consumer Healthcare will report full year earnings of $3.98 per share for the current financial year, with EPS estimates ranging from $3.95 to $4.00. For the next year, analysts forecast that the business will post earnings of $4.25 per share, with EPS estimates ranging from $4.20 to $4.30. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that that provide coverage for Prestige Consumer Healthcare.

Prestige Consumer Healthcare (NYSE:PBH) last released its quarterly earnings data on Thursday, August 5th. The company reported $1.14 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.87 by $0.27. The business had revenue of $269.10 million for the quarter, compared to the consensus estimate of $232.41 million. Prestige Consumer Healthcare had a return on equity of 13.25% and a net margin of 18.18%. The company’s revenue was up 17.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.86 EPS.

PBH has been the subject of several research reports. Royal Bank of Canada upped their target price on Prestige Consumer Healthcare from $107.00 to $123.00 and gave the stock a “sector perform” rating in a report on Friday, August 6th. Zacks Investment Research cut Prestige Consumer Healthcare from a “buy” rating to a “hold” rating and set a $55.00 price objective for the company. in a research note on Tuesday, July 13th. Finally, DA Davidson increased their price target on Prestige Consumer Healthcare from $52.00 to $61.00 and gave the company a “neutral” rating in a research note on Friday, August 6th. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $98.67.

Several large investors have recently bought and sold shares of PBH. Janney Montgomery Scott LLC grew its stake in shares of Prestige Consumer Healthcare by 83.4% in the first quarter. Janney Montgomery Scott LLC now owns 17,569 shares of the company’s stock worth $774,000 after acquiring an additional 7,988 shares in the last quarter. Great Lakes Advisors LLC acquired a new position in shares of Prestige Consumer Healthcare during the first quarter worth $3,392,000. Victory Capital Management Inc. grew its stake in shares of Prestige Consumer Healthcare by 9.2% during the first quarter. Victory Capital Management Inc. now owns 44,044 shares of the company’s stock worth $1,941,000 after purchasing an additional 3,701 shares in the last quarter. Dean Investment Associates LLC grew its stake in shares of Prestige Consumer Healthcare by 33.6% during the first quarter. Dean Investment Associates LLC now owns 57,091 shares of the company’s stock worth $2,517,000 after purchasing an additional 14,350 shares in the last quarter. Finally, Seizert Capital Partners LLC grew its stake in shares of Prestige Consumer Healthcare by 46.5% during the first quarter. Seizert Capital Partners LLC now owns 71,016 shares of the company’s stock worth $3,130,000 after purchasing an additional 22,538 shares in the last quarter.

Shares of NYSE PBH traded down $0.30 during trading hours on Friday, hitting $53.48. 3,903 shares of the company traded hands, compared to its average volume of 363,704. The company’s 50 day moving average price is $55.28 and its 200 day moving average price is $50.18. The stock has a market capitalization of $2.68 billion, a price-to-earnings ratio of 15.24, a price-to-earnings-growth ratio of 3.36 and a beta of 0.69. The company has a current ratio of 3.27, a quick ratio of 2.42 and a debt-to-equity ratio of 1.10. Prestige Consumer Healthcare has a 12 month low of $32.19 and a 12 month high of $60.57.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc engages in the marketing, sale, and distribution of pharmaceutical drugs and consumer products. It operates through the following segments: North American OTC Healthcare and International OTC Healthcare. The North American and International OTC Healthcare segments manages the following brands: BC/Goody’s, Beano, Boudreaux’s Butt Paste, Chloraseptic, Clear Eyes, Compound W, Debrox, DenTek, Dramamine, Efferdent, Fess, Fleet, Gaviscon, Hydralyte, Luden’s, Monistat, Nix, Pedia-Lax, and Summer’s Eve.

Recommended Story: Trade War

Get a free copy of the Zacks research report on Prestige Consumer Healthcare (PBH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Prestige Consumer Healthcare (NYSE:PBH)

Receive News & Ratings for Prestige Consumer Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prestige Consumer Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.